INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.
暂无分享，去创建一个
J. Schellens | M. Millward | M. Maio | A. Hansen | D. Cho | D. Rischin | V. Moreno | Helen Zhou | A. Hoos | H. Gan | T. Bauer | E. Angevin | P. Mayes | A. Olszanski | M. Barnette | S. Yadavilli | R. Jewell | J. Katz | C. Ellis | J. Martín-Liberal